Overview
- A Nature study using nearly 28,000 23andMe users linked a GLP1R variant to slightly greater BMI loss and a GIPR variant to nausea on tirzepatide, with effects described as modest and not ready to guide care.
- Doctors say GLP‑1 drugs are now used by about one in eight Americans and warn that risks can be higher for patients with Ehlers‑Danlos syndrome, PoTS or long COVID.
- Because these drugs slow stomach emptying, clinicians warn about gastroparesis and advise supervised diet changes only when needed to keep food moving.
- Rapid weight loss on GLP‑1s can strip lean muscle and upset electrolytes, so care teams often track protein intake, bone health, muscle mass and dosing.
- A separate Genome Medicine paper tied a PAM gene variant to weaker GLP‑1 effects in roughly 10% of people, reinforcing calls for more research rather than routine genetic testing.